|
1
|
Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma.
|
Gut
|
2007
|
1.76
|
|
2
|
Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.
|
J Viral Hepat
|
2007
|
1.20
|
|
3
|
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.
|
J Viral Hepat
|
2012
|
1.09
|
|
4
|
Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection.
|
Br J Cancer
|
2012
|
0.95
|
|
5
|
Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
|
Aliment Pharmacol Ther
|
2007
|
0.94
|
|
6
|
Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?
|
Int J Obes (Lond)
|
2006
|
0.90
|
|
7
|
Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.
|
J Viral Hepat
|
2006
|
0.84
|
|
8
|
Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area.
|
Oncogene
|
2006
|
0.83
|
|
9
|
High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
|
Gut
|
2005
|
0.82
|
|
10
|
Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.
|
J Viral Hepat
|
2004
|
0.79
|
|
11
|
Acute leukaemia in chronic hepatitis B patients with lamivudine therapy.
|
Int J Clin Pract
|
2004
|
0.79
|
|
12
|
Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion.
|
J Viral Hepat
|
2011
|
0.76
|